Literature DB >> 29167297

An official European Respiratory Society statement: pulmonary haemodynamics during exercise.

Gabor Kovacs1,2, Philippe Herve3, Joan Albert Barbera4,5, Ari Chaouat6,7, Denis Chemla8, Robin Condliffe9, Gilles Garcia8, Ekkehard Grünig10, Luke Howard11, Marc Humbert8, Edmund Lau12, Pierantonio Laveneziana13,14, Gregory D Lewis15, Robert Naeije16, Andrew Peacock17, Stephan Rosenkranz18, Rajeev Saggar19, Silvia Ulrich20, Dario Vizza21, Anton Vonk Noordegraaf22, Horst Olschewski23,2.   

Abstract

There is growing recognition of the clinical importance of pulmonary haemodynamics during exercise, but several questions remain to be elucidated. The goal of this statement is to assess the scientific evidence in this field in order to provide a basis for future recommendations.Right heart catheterisation is the gold standard method to assess pulmonary haemodynamics at rest and during exercise. Exercise echocardiography and cardiopulmonary exercise testing represent non-invasive tools with evolving clinical applications. The term "exercise pulmonary hypertension" may be the most adequate to describe an abnormal pulmonary haemodynamic response characterised by an excessive pulmonary arterial pressure (PAP) increase in relation to flow during exercise. Exercise pulmonary hypertension may be defined as the presence of resting mean PAP <25 mmHg and mean PAP >30 mmHg during exercise with total pulmonary resistance >3 Wood units. Exercise pulmonary hypertension represents the haemodynamic appearance of early pulmonary vascular disease, left heart disease, lung disease or a combination of these conditions. Exercise pulmonary hypertension is associated with the presence of a modest elevation of resting mean PAP and requires clinical follow-up, particularly if risk factors for pulmonary hypertension are present. There is a lack of robust clinical evidence on targeted medical therapy for exercise pulmonary hypertension.
Copyright ©ERS 2017.

Entities:  

Mesh:

Year:  2017        PMID: 29167297     DOI: 10.1183/13993003.00578-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  49 in total

1.  Differential Clinical Profiles, Exercise Responses, and Outcomes Associated With Existing HFpEF Definitions.

Authors:  Jennifer E Ho; Emily K Zern; Luke Wooster; Cole S Bailey; Thomas Cunningham; Aaron S Eisman; Kathryn M Hardin; Giovanna A Zampierollo; Petr Jarolim; Paul P Pappagianopoulos; Rajeev Malhotra; Matthew Nayor; Gregory D Lewis
Journal:  Circulation       Date:  2019-05-28       Impact factor: 29.690

2.  On the search for the right definition of heart failure with preserved ejection fraction.

Authors:  Agnieszka Kapłon-Cieślicka; Karolina Kupczyńska; Piotr Dobrowolski; Błażej Michalski; Miłosz J Jaguszewski; Waldemar Banasiak; Paweł Burchardt; Łukasz Chrzanowski; Szymon Darocha; Justyna Domienik-Karłowicz; Jarosław Drożdż; Marcin Fijałkowski; Krzysztof J Filipiak; Marcin Gruchała; Ewa A Jankowska; Piotr Jankowski; Jarosław D Kasprzak; Wojciech Kosmala; Piotr Lipiec; Przemysław Mitkowski; Katarzyna Mizia-Stec; Piotr Szymański; Agnieszka Tycińska; Wojciech Wańha; Maciej Wybraniec; Adam Witkowski; Piotr Ponikowski; On Behalf Of "Club 30" Of The Polish Cardiac Society
Journal:  Cardiol J       Date:  2020-09-28       Impact factor: 2.737

3.  The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction.

Authors:  Yogesh N V Reddy; Masaru Obokata; Brandon Wiley; Katlyn E Koepp; Caitlin C Jorgenson; Alexander Egbe; Vojtech Melenovsky; Rickey E Carter; Barry A Borlaug
Journal:  Eur Heart J       Date:  2019-12-01       Impact factor: 29.983

Review 4.  Performance and Interpretation of Invasive Hemodynamic Exercise Testing.

Authors:  C Charles Jain; Barry A Borlaug
Journal:  Chest       Date:  2020-05-28       Impact factor: 9.410

5.  Deliberating the Diagnostic Dilemma of Heart Failure With Preserved Ejection Fraction.

Authors:  Jennifer E Ho; Margaret M Redfield; Gregory D Lewis; Walter J Paulus; Carolyn S P Lam
Journal:  Circulation       Date:  2020-11-02       Impact factor: 29.690

6.  Right Ventricular Myofilament Functional Differences in Humans With Systemic Sclerosis-Associated Versus Idiopathic Pulmonary Arterial Hypertension.

Authors:  Steven Hsu; Kristen M Kokkonen-Simon; Jonathan A Kirk; Todd M Kolb; Rachel L Damico; Stephen C Mathai; Monica Mukherjee; Ami A Shah; Fredrick M Wigley; Kenneth B Margulies; Paul M Hassoun; Marc K Halushka; Ryan J Tedford; David A Kass
Journal:  Circulation       Date:  2018-01-19       Impact factor: 29.690

Review 7.  Pulmonary Vascular Disease: Hemodynamic Assessment and Treatment Selection-Focus on Group II Pulmonary Hypertension.

Authors:  Bhavadharini Ramu; Brian A Houston; Ryan J Tedford
Journal:  Curr Heart Fail Rep       Date:  2018-04

Review 8.  Cardiopulmonary Hemodynamics in Pulmonary Hypertension and Heart Failure: JACC Review Topic of the Week.

Authors:  Bradley A Maron; Gabor Kovacs; Anjali Vaidya; Deepak L Bhatt; Rick A Nishimura; Susanna Mak; Marco Guazzi; Ryan J Tedford
Journal:  J Am Coll Cardiol       Date:  2020-12-01       Impact factor: 24.094

9.  Exercise Pulmonary Hypertension Predicts Clinical Outcomes in Patients With Dyspnea on Effort.

Authors:  Jennifer E Ho; Emily K Zern; Emily S Lau; Luke Wooster; Cole S Bailey; Thomas Cunningham; Aaron S Eisman; Kathryn M Hardin; Robyn Farrell; John A Sbarbaro; Mark W Schoenike; Nicholas E Houstis; Aaron L Baggish; Ravi V Shah; Matthew Nayor; Rajeev Malhotra; Gregory D Lewis
Journal:  J Am Coll Cardiol       Date:  2020-01-07       Impact factor: 24.094

10.  Invasive Hemodynamic and Metabolic Evaluation of HFpEF.

Authors:  J Emanuel Finet; Erik H Van Iterson; W H Wilson Tang
Journal:  Curr Treat Options Cardiovasc Med       Date:  2021-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.